what is glp-1 r Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Endogenous cell membrane interactome mapping

[DOI] [PMC free article] [PubMed] [Google Scholar] 56.2025 Dietary Guidelines Advisory Committee

The findings, published in the journal Diabetes, Obesity and Metabolism, provide real-world context to previous randomized clinical trials indicating that patients who stopped semaglutide (sold under the brand names Ozempic/Wegovy) and tirzepatide (sold under the brand names Mounjaro/Zepbound) regained more than half of the weight they lost within 12 months

However, there are examples of drugs being withdrawn from the market as more long-term data comes to light

Enhancing Intestinal Barrier Efficiency: A Novel Metabolic Diseases Therapy